目的 研究注射用盐酸博莱霉素联合替莫唑胺胶囊治疗脑胶质瘤的临床疗效。方法 选取2015年1月—2018年1月海口市人民医院收治的60例脑胶质瘤患者为研究对象，将患者随机分为对照组和治疗组，每组各30例。对照组患者口服替莫唑胺胶囊，150 mg/m²，1次/d，连续服用5 d，然后停药23 d，再重复给药，1个治疗周期为28 d；治疗组患者在对照组基础上静脉注射注射用盐酸博莱霉素，1支/次，1次/d，连续给予2 d，然后停药26 d，再重复给药，1个治疗周期为28 d。两组患者均接受治疗2个周期。观察两组的临床疗效，比较两组的生命质量测定量表（QLQ-C30）评分和1年生存率。结果 治疗后，对照组和治疗组的临床有效率（ORR）分别为46.67%、63.33%，疾病控制率（DCR）分别为66.67%、86.67%，两组比较差异有统计学意义（P<0.05）。治疗后，两组认知评分、躯体评分、角色评分、社会功能评分、情绪评分均显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组认知评分、躯体评分、角色评分、社会功能评分、情绪评分明显高于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，对照组和治疗组1年生存率分别为46.67%、73.33%，两组比较差异有统计学意义（P<0.05）。结论 注射用盐酸博莱霉素联合替莫唑胺胶囊治疗脑胶质瘤具有较好的临床疗效，能改善生活质量，延长患者生存期，具有一定的临床推广应用价值。

Objective To study the efficacy of Bleomycin Hydrochloride for injection combined with Temozolomide Capsules in treatment of glioma. Methods Patients (60 cases) with glioma in Haikou People's Hospital from January 2015 to January 2018 were randomly divided into control and treatment groups, and each group had 30 cases. Patients in the control group were po administered with Temozolomide Capsules, 150 mg/m², once daily, continuous administration for 5 d, then withdrawal for 23 d, then repeated administration, a treatment cycle for 28 d. Patients in the treatment group were iv administered with Bleomycin Hydrochloride for injection on the basis of the control group, 1 branch/time, once daily, continuous administration for 2 d, then withdrawal for 26 d, then repeated administration, a treatment cycle for 28 d. Patients in two groups were treated for 2 cycles. After treatment, the clinical efficacies were evaluated, and QLQ-C30 score and 1-year survival rate in two groups were compared. Results After treatment, the ORR in the control and treatment groups were 46.67% and 63.33%, respectively, and the DCR in the control and treatment groups were 66.67% and 86.67%, respectively, and there was difference between two groups (P<0.05). After treatment, cognitive score, somatic score, role score, social function score, and emotional score in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the 1-year survival rate in the control and treatment groups were 46.67% and 73.33%, respectively, and there was difference between two groups (P<0.05). Conclusion Bleomycin Hydrochloride for injection combined with Temozolomide Capsules has clinical curative effect in treatment of glioma, can improve the quality of life, and prolong the survival time of patients, which has a certain clinical application value.